Allogeneic HSCT in acquired Pure Red Cell Aplasia
Data Quality Initiative of the SAAWP
Use of Eltrombopag in Aplastic Anaemia
CML transplanted in active blast crisis
CGD transplant outcome (update)
More News: CALM Study
A prospective Randomized multicenter study comparing horse Antithymocyte globuline (hATG) + Cyclosporine A (CsA) with or without Eltrombopag as front-line therapy for severe aplastic anemia patients.Study design: Open label randomised clinical trial
Primary objective: To investigate whether Eltrombopag added to standard immunosuppressive treatment increases the rate of early (at three months) complete response in untreated aplastic anemia patients.
Status: June 9, 2017
A study by the SAAWP
***Final call for data!***On June 1st, a final request has been sent to centres with patients receiving an allogeneic transplant for acquired Pure Red Cell Aplasia between 2000 and 2015. Transplants in this disease are rare and we hope to receive all data which is available.
Please send in your patient data using the prefilled form(s) before June 26th 2017 to the EBMT Data Office in Leiden via firstname.lastname@example.org
If you have questions, please contact Cora Knol of the EBMT Data Office via email@example.com.
A study by the SAAWP
***Final call for data!***The Severe Aplastic Anemia Working Party of the EBMT is interested in understanding the use of Eltrombopag in Europe. The aim of this study is to investigate the safety and efficacy of Eltrombopag in patients with SAA receiving the drug for initial immunosuppressive treatment or for incomplete response or to treat relapse.
Inclusion criteria for this study are:
For more information or to request the MED-C form, please contact Cora Knol/Paul Bosman via firstname.lastname@example.org
***Data request***PI: Aleksandar Radujkovic
The EBMT Chronic Malignancy Working Party (CMWP) would like to invite you to participate in a retrospective study on “Allogeneic stem cell transplantation for blast crisis CML in the era of tyrosine kinase inhibitors”, focusing on the identification of pretransplant prognostic factors.
As this is a relevant topic with very little published data we look forward to your participation. If you’re interested to participate in the data request, please contact Henric-Jan Blok: email@example.com
***Data request***PI: Robert Chiesa
Allogeneic haematopoietic stem cell transplantation (HSCT) has been increasingly used to treat patients with Chronic Granulomatous Disease (CGD).
Nevertheless the available data on the outcome of patients with CGD after HSCT is still limited. In fact, the last EBMT retrospective study on this subject described only 27 patients (Seger et al, Blood 2002), while over the last 15 years more than 400 patients with CGD have been transplanted.
We have the opportunity to update the results on HCT in CGD and to better define important prognostic factors, such as the role of conditioning regimen, stem cell donor and stem cell source.
If you’re interested to participate in the data request, please contact Henric-Jan Blok: firstname.lastname@example.org
CALM StudyCALM invoices can be send till 1st July 2017 (hard deadline)